

学术搜索

找到约 483 条结果 (用时0.08秒)

文章

我的图书馆

时间不限

2016以来

2015以来

2012以来

自定义范围...

按相关性排序

按日期排序

搜索所有网页

中文网页

简体中文网页

包括专利

包含引用

创建快讯

小提示: 只搜索中文(简体)结果, 可在 学术搜索设置、指定搜索语言

Biomarkers to predict the clinical efficacy of bevacizumab in cancer

AM Jubb, AL Harris - The lancet oncology, 2010 - Elsevier

... PFS=progression-free survival ... Data from a phase 2 study of sorafenib (a multi-tyrosine-kinase inhibitor, including VEGF receptors 1 and 2) in renal-cell ... The potential of DCE-MRI to yield surrogate markers for bevacizumab efficacy is, therefore, unknown, but preliminary data are ...

被引用次数: 213 相关文章 所有 6 个版本 引用 保存

[HTML] VEGF as a marker for outcome among advanced breast cancer patients receiving anti- aacrjournals.org 中的 [HTML]

VEGF therapy with bevacizumab and vinorelbine chemotherapy

HJ Burstein, YH Chen, LM Parker, J Savoie... - Clinical Cancer ..., 2008 - AACR

... The total accrual of 56 allowed the study to test a null hypothesis of 30 ... Our findings suggest that plasma VEGF could serve as a prognostic marker for tumor progression among such ...

Abstract/FREE Full Text. ↙ Holden SN, Ryan E, Keams, A, Holmgren E, Hurwitz H. Benefit from ...

被引用次数: 107 相关文章 所有 6 个版本 引用 保存

Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer researchgate.net 中的 [PDF]

Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer

B Guiu, JM Petit, F Bonnetain, S Ladoire, S Guiu... - Gut, 2010 - gut.bmj.com

... Univariate Cox proportional-hazards models of all potential baseline predictors were built ... to a first-line conventional chemotherapeutic regimen improved progression-free survival and ... extensive investigation, there are no known predictive biomarkers of VEGF-targeted treatment ...

被引用次数: 87 相关文章 所有 12 个版本 引用 保存

Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab aacrjournals.org 中的 [HTML]

Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab

PS Hegde, AM Jubb, D Chen, NF Li, YG Meng... - Clinical Cancer ..., 2013 - AACR

... the addition of bevacizumab to standard chemotherapy regimens significantly improves progression-free survival (PFS ... In addition, any conclusions about the predictive ability of total circulating VEGF-A ... currently ongoing and may clarify what, if any, role circulating VEGF-A has ...

被引用次数: 82 相关文章 所有 5 个版本 引用 保存

[HTML] ... cells and endothelial progenitors as predictive markers of clinical response to bevacizumab based first-line treatment in advanced colorectal cancer patients oxfordjournals.org 中的 [HTML]

Name of journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 24522

Manuscript Type: Therapeutic Advances

Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer

Azzariti A *et al.* Predictive biomarkers to antiangiogenetic colorectal cancer therapy

Amalia Azzariti, Letizia Porcelli, Oronzo Brunetti, Marzia Del Re, Vito Longo, Patrizia Nardulli, Michele Signorile, Jian-Ming Xu, Angela Calabrese, Anna Elisa Quatrone, Evaristo Maiello, Vito Lorusso, Nicola Silvestris

Amalia Azzariti, Letizia Porcelli, Michele Signorile, Anna Elisa Quatrone, ¹Clinical and Preclinical Pharmacology Laboratory, **National Cancer Research Centre Istituto Tumori Giovanni Paolo II, 70124 Bari, Italy**

Oronzo Brunetti, Vito Lorusso, Nicola Silvestris, Medical Oncology Unit, **National Cancer Research Centre Istituto Tumori Giovanni Paolo II, 70124 Bari, Italy**

Match Overview

Rank	Source	Words	Match %
1	Internet	139 words crawled on 07-Mar-2016 www.wjgnet.com	3%
2	Internet	71 words crawled on 16-Feb-2010 cancerres.aacrjournals.org	2%
3	CrossCheck	37 words Porcelli, Letizia, Anna E. Quatrone, Paola Mantuano, Maria G. Leo, Nicola Silvestris, Jean F. Rolland, Enza Carioglia,	1%
4	Internet	37 words crawled on 30-Jan-2016 iovs.arvojournals.org	1%
5	CrossCheck	29 words Sato, T. "Serum Concentrations of Bevacizumab (Avastin) and Vascular Endothelial Growth Factor in Infants With R..."	1%
6	CrossCheck	25 words Nugue, Guillaume, Marie Bidart, Marie Arlotto, Mireille Mousseau, François Berger, and Laurent Pelletier. "Monitorin..."	1%
7	CrossCheck	25 words Ranieri, Girolamo. "Molecular targeting agents associated with transarterial chemoembolization or radiofrequency a..."	1%
8	CrossCheck	22 words Sullivan, L. S., D. C. Koboldt, S. J. Bowne, S. Lang, S. H. Blanton, E. Cadena, C. E. Avery, R. A. Lewis, K. Webb-Jones,	1%
9	CrossCheck	21 words V Goede. "Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treat..."	1%



学术搜索

获得 1 条结果 (用时0.05秒)

文章

我的图书馆

时间不限

2016以来

2015以来

2012以来

自定义范围...

按相关性排序

按日期排序

搜索所有网页

中文网页

简体中文网页

包括专利

包含引用

创建快讯

小提示: 只搜索中文(简体)结果, 可在 学术搜索设置 指定搜索语言

Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: current evidence and future perspectives

A Custodio, J Barriuso, J de Castro... - Cancer treatment ..., 2013 - Elsevier

... GMT) and 12:00 pm EST (5:00 pm GMT) - it is not expected to ... the growth of solid tumours beyond the limits of oxygen diffusion from the existing vasculature. ... Vascular endothelial growth factor (VEGF) has been confirmed in several clinical trials as an important therapeutic target ...

被引用次数: 26 相关文章 所有 6 个版本 引用 保存

创建快讯

全部 新闻 图片 视频 购物 更多 ▾ 搜索工具

找到约 98,400 条结果 (用时 0.55 秒)

A pharmacokinetic binding model for bevacizumab and ...

www.ncbi.nlm.nih.gov > ... > Literature > PubMed Central (PMC) - 翻译此页

作者: E Panoilia - 2015 - 被引用次数: 4 - 相关文章

2015年2月17日 - Cancer **Chemotherapy** and Pharmacology ... A pharmacokinetic

binding model for **bevacizumab** and VEGF165 in **colorectal cancer** patients ...

Bevacizumab targets circulating **vascular endothelial growth factor** ... Model parameters may **not** be identifiable when limited experimental data on target, **total** and ...

Decreased peritherapeutic VEGF expression could be a ...

www.ncbi.nlm.nih.gov > ... > Literature > PubMed Central (PMC) - 翻译此页

作者: HL Tsai - 2015 - 被引用次数: 1 - 相关文章

2015年2月1日 - Methods: A **total** of 57 mCRC patients who underwent FOLFIRI

combined with ... Conclusions: Decreased peri-therapeutic **VEGF** expression in mCRC ... **VEGF** expression, metastatic **colorectal cancer**, **bevacizumab**, response ...

high EPHB4 gene expression [11] are **potential predictive** biomarkers in mCRC ...

Predicting response to vascular endothelial growth factor ...

bmccancer.biomedcentral.com/articles/10.../1471-2407-14-887 ▾ 翻译此页

作者: P Martin - 2014 - 被引用次数: 2 - 相关文章

Predicting response to **vascular endothelial growth factor** inhibitor and ... overall survival (OS) in metastatic **colorectal cancer** patients however currently there are **no** ...

Colorectal cancer Bevacizumab 2D-DIGE Biomarker Proteomics with oxaliplatin-based **chemotherapy** (median PFS 9.4 months with **bevacizumab** and ...

Full Text - Clinical Cancer Research

clincancerres.aacrjournals.org/content/19/4/929.full ▾ 翻译此页

作者: PS Hegde - 2013 - 被引用次数: 86 - 相关文章

2013年2月15日 - **No** correlation was found between circulating and tumor **VEGF-A** levels. ... Phase III studies have shown that the addition of **bevacizumab** to standard